Salvage therapy with Taxol in Patients with Ovarian carcinoma after Failure of Platinum-Based Chemotherapy.
- Author:
Yong Beom KIM
;
Dae Yeon KIM
;
Sang Young RYU
;
Jae Weon KIM
;
Noh Hyun PARK
;
Yong Sang SONG
;
Soon Beom KANG
;
Hyo Pyo LEE
- Publication Type:Original Article
- Keywords:
Ovarian cancer;
Taxol;
Salvage therapy
- MeSH:
Carboplatin;
Cisplatin;
Drug Therapy*;
Humans;
Magnetic Resonance Imaging;
Ovarian Neoplasms;
Paclitaxel*;
Salvage Therapy*
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1997;8(2):168-174
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND & AIMS: Management of ovarian carcinoma presents most commonly by surgery and subsequent platinum-based chemotherapy, but most patients will have either residual or recurrent disease. Taxol, a new antimicrotubule agent, has been indicated as a salvage measure after failure of first-line or subsequent chemotherapy. The purpose of this study is to investigate the efficacy and toxicity of Taxol used as a salvage therapy. MATERIALS & METHODS: Between January 1994 and Jun 1996, 19 patients aged 38-64 years(median 52) with ovarian carcinoma were given Taxol-containing regimen. Taxol was administered at a dose of 135mg/m2 intravenously with cisplatin or carboplatin every 3 weeks. The patients who treated with Taxol only were received 175mg/m2 intravenously with same interval. The median treatment cycle was 6.6 cycles(range, 3 to 15 cycles). Patient's response were evaluated with tumor marker(CA-125) and CT or MRI before and after chemotherapy. Responses and toxicities were defined according to the Gynecologic Oncology Group criteria. (continue)
